Recipharm Advanced Bio Capabilities Update September 2026: mRNA

Advancing RNA Therapeutics Through Integrated Development and Manufacturing

RNA therapeutics are transforming the treatment landscape across infectious disease, oncology, rare disease, and gene editing, but their successful development requires coordinated expertise across plasmid production, RNA synthesis, formulation, analytics, and manufacturing. This presentation will discuss how integrated development and GMP manufacturing strategies can accelerate the path from concept to clinic and commercialization. Recipharm provides end-to-end capabilities spanning plasmid DNA, mRNA, circular RNA, lipid nanoparticle (LNP) formulation, sterile fill-finish, analytical development, and regulatory support within a unified manufacturing framework.

Attendees will learn about platform technologies for RNA process development, in vitro transcription optimization, advanced LNP delivery systems, and emerging gene-editing workflows. The session will also highlight how integrated supply chains and continuous manufacturing innovations can reduce development risk, compress timelines, and support the scalable production of next-generation RNA medicines.